Marcus Granegger1, Bente Thamsen2, Thomas Schlöglhofer3, Selina Lach2, Andreas Escher4, Thorsten Haas5, Mirko Meboldt6, Martin Schweiger2, Michael Hübler2, Daniel Zimpfer7. 1. Department of Surgery, Pediatric Cardiovascular Surgery, Pediatric Heart Center, University Children's Hospital Zurich, Zurich, Switzerland; Children's Research Center, University Children's Hospital Zurich, Zurich, Switzerland; Biofluid Mechanics Laboratory, Institute for Imaging Science and Computational Modelling in Cardiovascular Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany. Electronic address: marcus.granegger@charite.de. 2. Department of Surgery, Pediatric Cardiovascular Surgery, Pediatric Heart Center, University Children's Hospital Zurich, Zurich, Switzerland; Children's Research Center, University Children's Hospital Zurich, Zurich, Switzerland. 3. Division of Cardiac Surgery, Department of Surgery, Medical University of Vienna, Vienna, Austria; Ludwig-Boltzmann-Cluster for Cardiovascular Research, Vienna, Austria. 4. Department of Surgery, Pediatric Cardiovascular Surgery, Pediatric Heart Center, University Children's Hospital Zurich, Zurich, Switzerland; Children's Research Center, University Children's Hospital Zurich, Zurich, Switzerland; Department of Mechanical and Process Engineering, Product Development Group Zurich, ETH Zurich, Zurich, Switzerland. 5. Children's Research Center, University Children's Hospital Zurich, Zurich, Switzerland; Department of Anesthesia, University Children's Hospital Zurich, Zurich, Switzerland. 6. Department of Mechanical and Process Engineering, Product Development Group Zurich, ETH Zurich, Zurich, Switzerland. 7. Division of Cardiac Surgery, Department of Surgery, Medical University of Vienna, Vienna, Austria.
Abstract
OBJECTIVE: Mechanical circulatory support has become a standard therapy for adult patients with end-stage heart failure. For pediatric patients, technologic development lags behind with no currently approved implantable rotary blood pump. As an alternative, the HeartWare Ventricular Assist Device (Medtronic, Minneapolis, Minn), originally designed for adults, is increasingly used in pediatric patients. The aim of this multicenter study was to assess in silico, in vitro, and in vivo the blood trauma potential of this pump in pediatric application. METHODS: Clinical outcome and indicators for in vivo blood trauma were investigated retrospectively in 14 pediatric patients with the HeartWare Ventricular Assist Device (age 11.3 ± 4.8 years). Blood trauma mechanisms of the HeartWare Ventricular Assist Device were examined in silico and in vitro at an adult and pediatric operating point (5 L/min and 2.5 L/min at 2800 rpm and 2200 rpm, respectively). The flow was simulated by computational fluid dynamics and analyzed regarding flow structures, shear stresses, and washout. Hemolysis was assessed with pumps circulating bovine blood in a temperate flow circuit. RESULTS: In the retrospective in vivo analysis, lactate dehydrogenase and D-dimer values were 1.5- and 3-fold elevated, respectively, compared with adult patients with the HeartWare Ventricular Assist Device. Major bleedings were observed in 42.9%, and suspected pump thrombosis and neurologic dysfunction were observed in 14.3% of all patients. In the pediatric conditions, simulations predicted elevated mechanical stress profile below 50 Pa, more stagnant flow field, and longer washout times within the pump. In vitro measurements revealed an increased normalized index of hemolysis (17.5 vs 8.2 mg/100 L; P = .0021). CONCLUSIONS: The HeartWare Ventricular Assist Device, operated at lower speeds and flows, induces elevated blood trauma. Further studies are required to assess the clinical implications of these findings.
OBJECTIVE: Mechanical circulatory support has become a standard therapy for adult patients with end-stage heart failure. For pediatric patients, technologic development lags behind with no currently approved implantable rotary blood pump. As an alternative, the HeartWare Ventricular Assist Device (Medtronic, Minneapolis, Minn), originally designed for adults, is increasingly used in pediatric patients. The aim of this multicenter study was to assess in silico, in vitro, and in vivo the blood trauma potential of this pump in pediatric application. METHODS: Clinical outcome and indicators for in vivo blood trauma were investigated retrospectively in 14 pediatric patients with the HeartWare Ventricular Assist Device (age 11.3 ± 4.8 years). Blood trauma mechanisms of the HeartWare Ventricular Assist Device were examined in silico and in vitro at an adult and pediatric operating point (5 L/min and 2.5 L/min at 2800 rpm and 2200 rpm, respectively). The flow was simulated by computational fluid dynamics and analyzed regarding flow structures, shear stresses, and washout. Hemolysis was assessed with pumps circulating bovine blood in a temperate flow circuit. RESULTS: In the retrospective in vivo analysis, lactate dehydrogenase and D-dimer values were 1.5- and 3-fold elevated, respectively, compared with adult patients with the HeartWare Ventricular Assist Device. Major bleedings were observed in 42.9%, and suspected pump thrombosis and neurologic dysfunction were observed in 14.3% of all patients. In the pediatric conditions, simulations predicted elevated mechanical stress profile below 50 Pa, more stagnant flow field, and longer washout times within the pump. In vitro measurements revealed an increased normalized index of hemolysis (17.5 vs 8.2 mg/100 L; P = .0021). CONCLUSIONS: The HeartWare Ventricular Assist Device, operated at lower speeds and flows, induces elevated blood trauma. Further studies are required to assess the clinical implications of these findings.
Authors: Thomas Palazzolo; Matthew Hirschhorn; Ellen Garven; Steven Day; Randy M Stevens; Joseph Rossano; Vakhtang Tchantchaleishvili; Amy L Throckmorton Journal: Artif Organs Date: 2022-04-14 Impact factor: 2.663
Authors: Malte Schöps; Sascha H Groß-Hardt; Thomas Schmitz-Rode; Ulrich Steinseifer; Daniel Brodie; Johanna C Clauser; Christian Karagiannidis Journal: J Transl Med Date: 2021-01-05 Impact factor: 5.531
Authors: Peng Fang; Jianjun Du; Andrea Boraschi; Silvia Bozzi; Alberto Redaelli; Marianne Schmid Daners; Vartan Kurtcuoglu; Filippo Consolo; Diane de Zélicourt Journal: Front Cardiovasc Med Date: 2022-03-11
Authors: Marcus Granegger; Thomas Schlöglhofer; Julia Riebandt; Gerald Schlager; Keso Skhirtladze-Dworschak; Erwin Kitzmüller; Ina Michel-Behnke; Günther Laufer; Daniel Zimpfer Journal: JTCVS Open Date: 2021-03-10
Authors: Andreas Escher; Young Choi; Fraser Callaghan; Bente Thamsen; Ulrich Kertzscher; Martin Schweiger; Michael Hübler; Marcus Granegger Journal: Ann Biomed Eng Date: 2020-03-30 Impact factor: 3.934